Guizhou Sanli Pharmaceutical Co Ltd (603439) — Cash Flow-to-Debt Ratio
Guizhou Sanli Pharmaceutical Co Ltd (603439) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥33.19 Million could theoretically repay 0% of its total liabilities (CN¥1.30 Billion) in one year. Check 603439 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Guizhou Sanli Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Guizhou Sanli Pharmaceutical Co Ltd across 12 annual periods. Also explore total assets of Guizhou Sanli Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Guizhou Sanli Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see 603439 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | CN¥107.07 Million | CN¥1.60 Billion | ▼ -70.7% |
| 2023 | 0.23x | CN¥276.70 Million | CN¥1.21 Billion | ▼ -54.9% |
| 2022 | 0.51x | CN¥293.29 Million | CN¥578.40 Million | ▲ +22.0% |
| 2021 | 0.42x | CN¥155.04 Million | CN¥372.93 Million | ▲ +82.0% |
| 2020 | 0.23x | CN¥63.25 Million | CN¥276.91 Million | ▼ -84.3% |
| 2019 | 1.46x | CN¥116.24 Million | CN¥79.72 Million | ▲ +13.6% |
| 2018 | 1.28x | CN¥75.35 Million | CN¥58.69 Million | ▲ +105.7% |
| 2017 | 0.62x | CN¥57.47 Million | CN¥92.07 Million | ▲ +55.5% |
| 2016 | 0.40x | CN¥35.10 Million | CN¥87.44 Million | ▲ +3.9% |
| 2015 | 0.39x | CN¥33.28 Million | CN¥86.14 Million | ▲ +9476.2% |
| 2014 | 0.00x | CN¥563.46K | CN¥139.67 Million | ▼ -98.2% |
| 2013 | 0.23x | CN¥30.09 Million | CN¥130.52 Million | — |